Ronan O'Hagan

[Ronan O'Hagan @ohaganr]

Fantastic to work with so many #patientcentric organizations to detail a framework that will enhance #PatientCare and improve the quality of #RealWorldEvidence

[Friends of Cancer Research @CancerResrch]

Just announced, new @CancerResrch publication in @JCOCCI_ASCO detailing a framework to align ePRO data capture assessing the value of ePROs for improving #patient outcomes. https://t.co/PYC8dB2fiR #RWE #RWEFriends #JCOCCI

[Ronan O'Hagan @ohaganr]

Happy to see our collaboration with @CancerResrch published in @JCOCCI_ASCO detailing a framework to align ePRO data capture and the value of ePRO to improve patient outcomes. Click to view the latest findings. https://t.co/ckDBg7Nkvw #RWE #RWEFriends #JCOCCI @apricity_health

[Ronan O'Hagan @ohaganr]

@RonDePinho Really nice illustration of interaction between 2 key immune axes, the T cell and myeloid cell compartments. Also highlights need to identify the patients that will benefit from each specific combination of therapies as we move this concept to the clinic #precision #Immunotherapy

[Ronan O'Hagan @ohaganr]

Thanks to organizers of MedInvest Oncology Conference this week for invite to present keynote talk on #oncology #drugdiscovery #drugdevelopment including focus on #precisionmedicine in #immunotherapy and critical role of #diversityandinclusion in oncology R&D #biotech #oncology

[Ronan O'Hagan @ohaganr]

It was my pleasure to participate in #SITC22 Roundtable on Diversity in Clinical Trials on behalf of @apricity_health. Thanks to so many insightful participants, and hopefully our input will help support @sitcancer mission to address #healthequity in cancer #Immunotherapy

[Ronan O'Hagan @ohaganr]

Clinical trial enrollment is not only about access to potentially breakthrough medicines it also can help to overcome limitations in health insurance since the sponsor typically pays…if it makes sense medically the option should be offered @NCICRCHD #healthequity #cancercare

[Apricity Health @apricity_health]

Caucasian and African American patients sign up for clinical trials at rates of 55.1% and 58.4% respectively, "IF OFFERED THE OPPORTUNITY."
https://t.co/cdQb3WD8kA

[Ronan O'Hagan @ohaganr]

Fantastic to see the expansion of @SU2C #healthequity support as we work towards equity in cancer care and inclusiveness in cancer research #StandUpToCancer

[Stand Up To Cancer @SU2C]

We continue to make progress towards our mission with the announcement of these two NEW teams!

To learn more and stay up to date on the latest at #StandUpToCancer, visit https://t.co/uMz6obTiar

[Ronan O'Hagan @ohaganr]

@FDApanels Diversity in clinical trials is an important issue @FDApanels, but let’s not kid ourselves that clinical trials run in US are diverse or represent the diversity of people living with cancer who need treatments that will work for them #Diversity #oncology #biotech #clinicaltrials

[Ronan O'Hagan @ohaganr]

@ldtimmerman @TakedaPharma @fredhutch Great job Kannan!!!

[Ronan O'Hagan @ohaganr]

Nice summary of the discussion. Zoom not a fun as sunny San Diego but always a privilege to interact with the amazing SU2C team members #SU2C #DreamTeam #CancerResearch

[Elizabeth Plimack MD @ERPlimackMD]

While it wasn't the same as being in person, the 2022 @SU2Cscience Scientific Summit Community Gathering was inspiring as always. Excellent talk from @NCIDirector on strides being made, and work yet to be done. A few key points that resonated. 🧵 1/7

[Ronan O'Hagan @ohaganr]

@PDRennert It would be great for patients if many were successful, and perhaps even better if that led to pricing competition. Innovation and differentiation should earn a benefit if a few stand out for particular patients. What will the PD(L)-1 landscape teach us here? #innovation

[Ronan O'Hagan @ohaganr]

What progress have we made bringing precision to IO therapies? Perhaps some for mono tx but how do we support IO-IO combinations? Interesting perspective from “way” back in 2016 frames some key questions #immunology #precision #biomarker https://t.co/uVhAcb0Ig2

[Ronan O'Hagan @ohaganr]

@Arsenal @ArsenalWFC @VivianneMiedema @leahcwilliamson

[Ronan O'Hagan @ohaganr]

@endpts The broad success of PD(L)-1 drugs is great for patients. We need to figure out how to build on that & more of the same may not do it. Understanding the patient and their tumor immune state could reveal opportunities for precision in IO therapy #Immunotherapy #oncology #patients

[Ronan O'Hagan @ohaganr]

Great summary of the potential of oncolytic viruses for cancer therapy and in particular the multi-arming potential of myxomavirus from Oncomyx CSO Leslie Sharp on #scienceboard #immuneoncology https://t.co/X7L9Gsnqh0

[Ronan O'Hagan @ohaganr]

@aledmedwards Could the SGC create a grant structure or a collaboration model for this type of truly novel work? SGC credibility combined with creative minds could increase POS of funding and turning those 2 papers into 10K

[Ronan O'Hagan @ohaganr]

Xilio’s IND application for XTX101, our tumor selective anti-CTLA-4 antibody, has been accepted by the FDA. We look forward to beginning Phase 1 development to evaluate the potential XTX101 may offer as both monotherapy and combo for patients with cancer. https://t.co/LpNuuypIA7

[Ronan O'Hagan @ohaganr]

@maude_tessier @OtherReneRusso @xiliotx Thanks Maude

[Ronan O'Hagan @ohaganr]

A long road but a valuable new option for RCC patients. Congrats to the AVEO team present and past who helped advance tivo

[AVEO Oncology @AVEOOncology]

$AVEO is proud to announce the #FDA approval of a new treatment option for adult patients with relapsed or refractory advanced #RCC following two or more prior systemic therapies.

Press release: https://t.co/wfYfK8QfBL

Prescribing Information: https://t.co/H8XLaDqmr0

[Endpoints News @endpts]

About three years after joining the search for IL-2  and CTLA-4 therapies without all those nasty side effects, Xilio Therapeutics has teed up $95 million to drive its two lead candidates into the clinic.

https://t.co/eAw03tkJJj